Early results from a Phase I trial of an experimental cancer vaccine, ELI-002, show promising results for treating recurring pancreatic and colorectal cancers. The vaccine, targeting KRAS gene mutations, triggered an immune response in 85% of participants, significantly improving survival and recurrence-free periods. A larger Phase II trial is underway, with results anticipated in 2026. If confirmed, this off-the-shelf vaccine could benefit a significant portion of patients with these cancers.

Prepared by Olivia Bennett and reviewed by editorial team.